Hepatitis C drug trial halted after patient death
Bristol-Myers Squibb has halted development of a potential hepatitis C drug after nine participants in a clinical trial of the therapy were hospitalised and one died (see press release). Read more
Bristol-Myers Squibb has halted development of a potential hepatitis C drug after nine participants in a clinical trial of the therapy were hospitalised and one died (see press release). Read more
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells